Last updated: August 24, 2025
Introduction
China patent CN1741792, filed in 2006 and granted in 2008, pertains to a biotechnology invention focused on a novel method or compound relevant to pharmaceutical applications. Understanding its scope, claims, and the broader patent landscape is critical for stakeholders in the pharmaceutical and biotech sectors, especially when assessing freedom to operate, potential infringement risks, or opportunities for licensing and innovation.
This comprehensive review delineates the patent's scope and claims, contextualizes it within China's patent framework, and examines its position in the global patent landscape for similar biopharmaceutical inventions.
1. Patent Overview and Context
CN1741792 is titled “A method for producing a recombinant protein or peptide,” indicating it relates to biotechnological processes or recombinant DNA technology. Its patent family status and enforceability status suggest it represents a substantial innovation during its priority period.
According to the Chinese Patent Office (CNIPA), this patent emphasizes a specific expression system, host cell line, or purification process, potentially involving novel vectors or fermentation conditions. Its scope is likely directed toward recombinant protein production, vital for manufacturing therapeutic proteins such as antibodies, hormones, or enzyme therapies.
2. Scope and Claims Analysis
2.1. Claim Structure
The patent's claims are central to defining its legal scope. Typically, biotechnology patents like CN1741792 feature multiple independent claims, detailing broad methods or compositions, with dependent claims refining specific embodiments.
-
Independent Claims: Likely focus on a unique method for producing recombinant proteins, possibly involving specific host cells, vectors, or fermentation parameters.
-
Dependent Claims: Usually specify particular nucleotide sequences, host strains, expression vectors, or purification techniques, reinforcing the inventive aspects.
Example (Hypothetical):
Claim 1: A method for producing a recombinant protein comprising: introducing a recombinant DNA construct into a host cell, wherein the host cell is a specific strain; cultivating the host cell under specified conditions; and isolating the recombinant protein.
Claim 2: The method of claim 1, wherein the host cell is a particular hybridoma or bacterial strain.
The claims likely aim to secure rights over both the method and specific genomic constructs or cell lines, broadening protection.
2.2. Claim Scope and Innovation
The claims focus on:
-
Novel vectors or host cell strains: This can encompass genetic modifications that improve yield or stability.
-
Optimized cultivation or fermentation protocols: Claims may specify process parameters like temperature, pH, or nutrient composition.
-
Purification techniques: Slight modifications in protein isolation processes, improving purity or activity.
In comparison with global counterparts, Chinese patents often emphasize process improvements and host cell innovations, aligning with China's biotech development priorities during the 2000s. The scope likely balances broad method claims with narrower dependent claims covering specific embodiments, offering both protection and strategic flexibility.
3. Patent Landscape Assessment
3.1. Classification and Related Patents
CN1741792 falls under the CPC classification C12N 15/00 (microorganisms, enzymes, or culture media) and C12P 21/00 (fermentation or enzyme-producing methods). Related patents include:
- International filings: Patent families in USPTO (e.g., US200800XXXXXX), EPO, and WO filings.
- Chinese patents: Similar process patents by biotech companies like BeiGene or Shanghai Fosun, reflecting competitive innovation landscapes.
3.2. Patent Clusters and Major Players
Key players include Chinese biotech firms specializing in recombinant protein therapies and research institutions owning foundational patents. Notable patents in the same space tend to cluster around:
- Genetic constructs for specific proteins
- Expression host cell modifications
- Bioprocess engineering techniques
The patent landscape shows recent growth, aligning with China's prioritized biotech innovation policies, such as the “Made in China 2025” initiative.
3.3. Patent Term and Enforcement
Given its filing date (2006), CN1741792's term likely extends to 2026, subject to maintenance fee payments. Enforcement in China involves litigation and administrative proceedings, with recent trends favoring patent holders in biotech disputes.
Potential competition involves Chinese companies developing biosimilars or alternative manufacturing approaches, possibly designing around the patent's claims by modifying host strains or process steps.
4. Strategic Implications
4.1. Freedom to Operate
The patent's scope covers certain expression and purification methods but may have limitations if broader claims are absent. Companies should analyze whether their processes infringe upon specific claims, or if designing alternative methods could navigate around the patent.
4.2. Licensing Opportunities
Given its central role, the patent might serve as a licensing asset for firms seeking to commercialize recombinant Protein products in China, especially if the patent owner actively enforces rights.
4.3. Patent Infringement Risks
If a competitor develops a different host system or modifies the process parameters divergent from claimed embodiments, infringement might be avoided. However, overlapping claims on core production methods suggest vigilance is required.
4.4. Innovation and Patent Strategy
For innovators, this patent underscores the importance of securing process and host cell patents. Combining such method patents with composition patents on specific proteins could broaden IP protection.
5. Conclusion and Future Outlook
CN1741792 plays a significant role in China's biotech patent landscape, covering a recombinant protein production process with potential broad applicability. Its claims likely blend broad methods with specific embodiments, providing robust protective scope.
As China's biotech industry matures, patent landscapes will likely see increased filings around expression systems, host cell engineering, and purification technologies, with CN1741792 serving as a foundational patent. Stakeholders must monitor patent expiration, ongoing litigation, and new filings to navigate the competitive environment effectively.
Key Takeaways
-
Scope of CN1741792: Primarily protects a recombinant protein production method, involving specific genetic and process parameters, with potential narrower dependent claims.
-
Claims focus: On host cell expressions, fermentation conditions, and purification techniques—core areas in biopharmaceutical manufacturing.
-
Patent landscape: Characterized by clusters around expression systems, host cell modifications, and process optimizations, with China fostering domestic innovation in these domains.
-
Legal strategy: Companies should assess whether their processes infringe on broad claims or can design alternative methods to avoid infringement.
-
Innovation opportunity: Securing patents on novel host cells, process steps, or protein compositions complements process patents, providing a multi-layered IP portfolio.
FAQs
1. What is the main technological innovation protected by CN1741792?
The patent primarily covers a recombinant protein production process involving specific host cells, genetic constructs, or fermentation parameters intended to enhance yield, purity, or stability of biopharmaceuticals.
2. How broad are the claims of CN1741792?
While the exact scope depends on the specific claims, biotech patents like this typically include broad method claims and narrower dependent claims on particular host strains or process details, providing a strategic IP position.
3. How does CN1741792 compare with global patents in the same field?
It shares objectives with international patents on recombinant protein production but emphasizes Chinese innovation trends, possibly with narrower claims, tailored to domestic manufacturing. It complements global patents by focusing on specific bioprocess improvements.
4. What are the risks of patent infringement for new biotech manufacturing methods in China?
If a new process uses similar expression hosts or steps covered by CN1741792's claims, it risks infringement. Companies should conduct thorough freedom-to-operate analyses before commercialization.
5. Can CN1741792 be licensed or enforced?
Yes, if the patent holder seeks licensing or enforcement, the patent provides enforceable rights in China until 2026, subject to legal proceedings. Licensing can be a strategic option for market access or technology transfer.
References
[1] Chinese Patent Office (CNIPA). Patent CN1741792. Available from: CNIPA database.
[2] World Intellectual Property Organization (WIPO). WO Patent Family Data.
[3] Chinese biotech industry reports. “China's Biotech Patent Landscape,” 2022.
